Status
Conditions
Treatments
About
Urinary Urge Incontinence (UUI) is the involuntary urine loss associated with a strong sensation to void.
UUI usually associated with reduced bladder capacity.
The pathophysiology is unclear.
Pelvic floor muscle dysfunction and detrusor instability have been suggested as possible mechanisms.
Standard treatment includes anticholinergic medication and behavior modification.
The study aims to compare the long term effectiveness of 4 different approaches to the treatment of women with Urge Urinary Incontinence (UUI):
Study variables will include: impairment ratings, quality of life, and cost-effectiveness.
This study addresses three issues:
Full description
The study has 3 phases: Before treatment (phase I), immediately after 3 months of treatment (phase II), and 1 year post-entry (phase III)
Women with UUI will be divided randomly into one of the four treatment groups. Every subject will participate in 4 visits. The drug group treatment consists of administration of tolterodine SR 4 mg daily for 3 months. Subjects who assigned to the pelvic floor rehabilitation, pelvic floor muscle training, and bladder training groups will be treated via 4 visits to a physical therapist, who is trained in the procedures. The chief researcher (RK) will be blinded to the treatment groups and will perform the outcome measures in all phases.
Study variables will include impairment ratings, quality of life, and cost-effectiveness
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
164 participants in 4 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal